Outcome of Patients with Acute Myeloid Leukemia Following Failure of Front-Line Venetoclax Plus Hypomethylating Agent Therapy

被引：3
|
作者：
Ilyas, Rimal [1 ]
Johnson, Isla McKerrow [1 ]
McCullough, Kristen [2 ]
Al-Kali, Aref [3 ]
Alkhateeb, Hassan B. [3 ]
Begna, Kebede [3 ]
Mangaonkar, Abhishek A. [3 ]
Litzow, Mark R. [3 ]
Hogan, William J. [3 ]
Shah, Mithun, V [3 ]
Patnaik, Mrinal M. M. [3 ]
Pardanani, Animesh [3 ]
Tefferi, Ayalew [3 ]
Gangat, Naseema [3 ]
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Mayo Clin, Div Pharmacol, Rochester, MN USA
[3] Mayo Clin, Div Hematol, Rochester, MN USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-165491
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1286 / 1287
页数：2
相关论文
共 50 条
  • [1] Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy
    Gangat, Naseema
    Ilyas, Rimal
    Johnson, Isla M.
    McCullough, Kristen
    Al-Kali, Aref
    Alkhateeb, Hassan B.
    Begna, Kebede H.
    Mangaonkar, Abhishek
    Litzow, Mark R.
    Hogan, William
    Shah, Mithun
    Patnaik, Mrinal M.
    Pardanani, Animesh
    Tefferi, Ayalew
    HAEMATOLOGICA, 2023, 108 (11) : 3170 - 3174
  • [2] Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens
    Maiti, Abhishek
    Rausch, Caitlin R.
    Cortes, Jorge E.
    Pemmaraju, Naveen
    Daver, Naval G.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Borthakur, Gautam
    Naqvi, Kiran
    Ohanian, Maro
    Short, Nicholas J.
    Alvarado, Yesid
    Kadia, Tapan M.
    Takahashi, Koichi
    Yilmaz, Musa
    Jain, Nitin
    Kornblau, Steven
    Montalban-Bravo, Guillermo
    Sasaki, Koji
    Andreeff, Michael
    Bose, Prithviraj
    Ferrajoli, Alessandra
    Issa, Ghayas C.
    Jabbour, Elias J.
    Masarova, Lucia
    Thompson, Philip A.
    Wang, Sa
    Konoplev, Sergej
    Pierce, Sherry A.
    Ning, Jing
    Qiao, Wei
    Welch, John S.
    Kantarjian, Hagop M.
    DiNardo, Courtney D.
    Konopleva, Marina Y.
    HAEMATOLOGICA, 2021, 106 (03) : 894 - 898
  • [3] Molecular Predictors of Response and Survival in Patients with Relapsed/Refractory Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy
    Johnson, Isla McKerrow
    Ilyas, Rimal
    McCullough, Kristen
    Al-Kali, Aref
    Alkhateeb, Hassan B.
    Begna, Kebede
    Mangaonkar, Abhishek A.
    Litzow, Mark R.
    Hogan, William J.
    Shah, Mithun, V
    Patnaik, Mrinal M.
    Pardanani, Animesh
    Tefferi, Ayalew
    Gangat, Naseema
    BLOOD, 2022, 140 : 3233 - 3234
  • [4] Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent
    Steinauer, Nickolas
    McCullough, Kristen
    Al-Kali, Aref
    Alkhateeb, Hassan B.
    Begna, Kebede H.
    Mangaonkar, Abhishek A.
    Saliba, Antoine N.
    Torghabeh, Mehrdad
    Litzow, Mark R.
    Hogan, William J.
    Shah, Mithun
    Patnaik, Mrinal M.
    Pardanani, Animesh
    Badar, Talha
    Murthy, Hemant
    Foran, James
    Yi, Cecilia Arana
    Tefferi, Ayalew
    Gangat, Naseema
    HAEMATOLOGICA, 2024, 109 (08) : 2706 - 2710
  • [5] Survival and Prognosis Among 301 Patients with Newly-Diagnosed Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy
    Karrar, Omer
    Iftikhar, Moazah
    McCullough, Kristen
    Johnson, Isla
    Abdelmagid, Maymona
    Al-Kali, Aref
    Alkhateeb, Hassan
    Begna, Kebede
    Mangaonkar, Abhishek A.
    Saliba, Antoine
    Hefazi, Mehrdad
    Litzow, Mark R.
    Hogan, William J.
    Shah, Mithun V.
    Patnaik, Mrinal M.
    Pardanani, Animesh D.
    Badar, Talha
    Murthy, Hemant S.
    Foran, James M.
    Palmer, Jeanne
    Sproat, Lisa
    Khera, Nandita
    Yi, Cecilia Y. Arana
    Tefferi, Ayalew
    Gangat, Naseema
    BLOOD, 2023, 142
  • [6] Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm
    Tremblay, Douglas
    Feld, Jonathan
    Dougherty, Mikaela
    Czaplinska, Tina
    Sanchez, Gillian
    Kremyanskaya, Marina
    Bar-Natan, Michal
    Shih, Alan H.
    Keyzner, Alla
    Mascarenhas, John
    LEUKEMIA RESEARCH, 2020, 98
  • [7] Venetoclax plus Cladribine plus Low-Dose Cytarabine in Acute Myeloid Leukemia Relapsed or Refractory to Venetoclax plus Hypomethylating Agent
    Steinauer, Nickolas
    McCullough, Kristen
    Al-Kali, Aref
    Alkhateeb, Hassan
    Begna, Kebede
    Mangaonkar, Abhishek A.
    Saliba, Antoine
    Hefazi, Mehrdad
    Litzow, Mark R.
    Hogan, William J.
    Shah, Mithun V.
    Pardanani, Animesh D.
    Badar, Talha
    Murthy, Hemant S.
    Foran, James M.
    Yi, Cecilia Y. Arana
    Tefferi, Ayalew
    Gangat, Naseema
    BLOOD, 2023, 142
  • [8] Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax
    Asghari, Hannah
    Lee, Dasom
    Deutsch, Yehuda E.
    Chan, Onyee
    Al Ali, Najla
    Boisclair, Stephanie
    Brahim, Amanda
    Padron, Eric
    Kuykendall, Andrew T.
    List, Alan F.
    Fernandez, Hugo F.
    Lancet, Jeffrey E.
    Sallman, David A.
    Komrokji, Rami S.
    Sweet, Kendra L.
    Talati, Chetasi
    BLOOD, 2019, 134
  • [9] Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia
    Arslan, Shukaib
    Zhang, Jianying
    Dhakal, Prajwal
    Moran, Jenna
    Naidoo, Nuthana
    Lombardi, Jennifer
    Pullarkat, Vinod
    Stein, Anthony S.
    Marcucci, Guido
    Yaghmour, George
    Bhatt, Vijaya R.
    Fathi, Amir T.
    Aldoss, Ibrahim
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (03) : E59 - E63
  • [10] Outcomes By Best Response with Hypomethylating Agent Plus Venetoclax in Adults with Previously Untreated Acute Myeloid Leukemia
    Volpe, Virginia Olivia
    Jain, Akriti G.
    Chan, Onyee
    Padron, Eric
    Sallman, David A.
    Komrokji, Rami S.
    Lancet, Jeffrey E.
    Sweet, Kendra
    BLOOD, 2021, 138
12345